FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bryan Roth

Research Profile

Chemicals & Drugs

Living Beings

Rats
Mouse

Concepts & Ideas

Co-author Network

Publications

TOP 3
Martilias S Farrell; Bryan L Roth
Pharmacosynthetics: Reimagining the pharmacogenetic approach.
Dahlia R Weiss; Xiao Zhu; Ryan Strachan; Seungkirl Ahn; Andrew Kleist; Robert J Lefkowitz; Bryan L Roth; Maria F Sassano; Brian K Shoichet
Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor.
Prabhakar R Polepally; Bryan L Roth; Eyal Vardy; Kate White; Daneel Ferreira; Jordan K Zjawiony
Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bryan Roth (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Martilias S Farrell; Bryan L Roth
Pharmacosynthetics: Reimagining the pharmacogenetic approach.
Brain research 2013;1511():6-20.
2013: Dahlia R Weiss; Xiao Zhu; Ryan Strachan; Seungkirl Ahn; Andrew Kleist; Robert J Lefkowitz; Bryan L Roth; Maria F Sassano; Brian K Shoichet
Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor.
ACS chemical biology 2013;8(5):1018-26.
2013: Prabhakar R Polepally; Bryan L Roth; Eyal Vardy; Kate White; Daneel Ferreira; Jordan K Zjawiony
Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
Bioorganic & medicinal chemistry letters 2013;23(10):2860-2.
2013: Martilias S Farrell; Jean-Marc Guettier; Xi-Ping Huang; Sandy J Hufeisen; Hyeong-Min Lee; Sheryl S Moy; Randal J Nonneman; Ying Pei; Noah Sciaky; Arkeen Simmons; Daniel J Urban; Yehong Wan; Jürgen Wess; Prem N Yadav; Nicole Calakos; Marc G Caron; Tanya L Daigle; Bryan L Roth
A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2013;38(5):854-62.
2013: Maria F Sassano; Allison K Doak; Bryan L Roth; Brian K Shoichet
Colloidal aggregation causes inhibition of G protein-coupled receptors.
Journal of medicinal chemistry 2013;56(6):2406-14.
2013: Henry Lin; Bryan L Roth; Maria F Sassano; Brian K Shoichet
A pharmacological organization of G protein-coupled receptors.
Nature methods 2013;10(2):140-6.
2013: Eyal Vardy; Bryan L Roth
Conformational ensembles in GPCR activation.
Cell 2013;152(3):385-6.
2013: Bryan L Roth; Vincent Setola; Ric Treble; Warunya Arunotayanun; Simon Gibbons; Xi-Ping Huang; Les Iversen
The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor.
PloS one 2013;8(3):e59334.
2013: Ojas A Namjoshi; Hanna Ng; Sundari K Rallapalli; Joachim Ramerstorfer; Bryan L Roth; James K Rowlett; Werner Sieghart; Zdravko Varagic; Zhi-jian Wang; Edward Merle Johnson; Yun-Teng Johnson; Samarpan Majumder; James M Cook
Search for α3β₂/₃γ2 subtype selective ligands that are stable on human liver microsomes.
Bioorganic & medicinal chemistry 2013;21(1):93-101.
2012: Kate L White; Bryan L Roth
Psychotomimetic effects of kappa opioid receptor agonists.
Biological psychiatry 2012;72(10):797-8.
2012: Xin Chen; Stephen Frye; Xu Bai; Meng Chen; Bryan L Roth; Maria F Sassano; Vincent Setola; William C Wetsel; Lianyou Zheng; Jian Jin
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
Journal of medicinal chemistry 2012;55(16):7141-53.
2012: Elisabet Gregori-Puigjané; Jerome Hert; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Vincent Setola; Brenda A Crews; Brian Shoichet
Identifying mechanism-of-action targets for drugs and probes.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(28):11178-83.
2012: Xue Y Zhu; Jagan R Etukala; Suresh V K Eyunni; Bryan L Roth; Vincent Setola; Seth Y Ablordeppey
Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.
European journal of medicinal chemistry 2012;53():124-32.
2012: Rima Hajjo; Bryan L Roth; Vincent Setola; Alexander Tropsha
Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
Journal of medicinal chemistry 2012;55(12):5704-19.
2012: Jun Li; Bryan L Roth; Vincent Setola; Charles L Burandt; Daneel Ferreira; Frank R Fronczek; Jordan K Zjawiony
Bis-spirolabdane diterpenoids from Leonotis nepetaefolia.
Journal of natural products 2012;75(4):728-34.
2012: Kwakye Peprah; Bryan L Roth; Vincent Setola; Xue Y Zhu; Jagan R Etukala; Suresh V K Eyunni; Seth Y Ablordeppey
Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.
Bioorganic & medicinal chemistry 2012;20(5):1671-8.
2012: HM Lee; Bryan L Roth
Hallucinogen actions on human brain revealed.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(6):1820-1.
2012: Kwakye Peprah; Bryan L Roth; Vincent Setola; Xue Y Zhu; Suresh V K Eyunni; Seth Y Ablordeppey
Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.
Bioorganic & medicinal chemistry 2012;20(3):1291-7.
2012: Christian Laggner; Henry Lin; Daniel L Minor; Randall T Peterson; Bryan L Roth; Vincent Setola; Chung Yan J Cheung; John J Irwin; Michael J Keiser; David Kokel; Alexandra Tolia; Brian K Shoichet
Chemical informatics and target identification in a zebrafish phenotypic screen.
Nature chemical biology 2012;8(2):144-6.
2012: Adam Pigott; Bryan L Roth; Stewart Frescas; Xi-Ping Huang; John D McCorvy; David E Nichols
trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family.
Beilstein journal of organic chemistry 2012;8():1705-9.
2012: Hu Zhu; Craig A Stockmeier; Patrick F Sullivan; Daniel J Urban; Zefeng Wang; Jared Blashka; Lesa Dieter; George J Jurjus; Wesley K Kroeze; Gouri J Mahajan; Matthew T McPheeters; Piotr Mieczkowski; James C Overholser; Grazyna Rajkowska; Bryan L Roth
Quantitative analysis of focused a-to-I RNA editing sites by ultra-high-throughput sequencing in psychiatric disorders.
PloS one 2012;7(8):e43227.
2011: John A Allen; Xu Bai; Marc G Caron; Xin Che; Meng Chen; Xin Chen; Bo Feng; Stephen V Frye; Xi-ping Huang; Jonathan A Javitch; Niels H Jensen; Sean Peterson; Bryan L Roth; Maria F Sassano; Vincent Setola; William C Wetsel; Prem N Yadav; Julianne M Yost; Jian Jin
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(45):18488-93.
2011: Jens Carlsson; Ryan G Coleman; Hao Fan; John J Irwin; Bryan L Roth; Andrej Sali; Avner Schlessinger; Vincent Setola; Brian Shoichet
Ligand discovery from a dopamine D3 receptor homology model and crystal structure.
Nature chemical biology 2011;7(11):769-78.
2011: Bryan L Roth
Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.
Neuropharmacology 2011;61(3):348-54.
2011: Eyal Vardy; Bryan L Roth
Vision and olfaction say UNC-le to G proteins.
Nature neuroscience 2011;14(7):805-6.
2011: Sarah C Rogan; Bryan L Roth
Remote control of neuronal signaling.
Pharmacological reviews 2011;63(2):291-315.
2011: Prem N Yadav; Atheir I Abbas; Martilias S Farrell; Vincent Setola; Noah Sciaky; Xi-Ping Huang; Wesley K Kroeze; LaTasha K Crawford; David A Piel; Michael J Keiser; John J Irwin; Brian K Shoichet; Evan S Deneris; Jay A Gingrich; Sheryl G Beck; Bryan L Roth
The presynaptic component of the serotonergic system is required for clozapine's efficacy.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2011;36(3):638-51.
2011: J A Allen; M Farrell; Vincent Setola; P N Yadav; Bryan L Roth
Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo.
Translational psychiatry 2011;1():e33.
2011: Kalpana Gupta; Ritu Ramdeo; Sonia Rana; Bryan L Roth; William Tse; Mukesh K Agarwal; Munna L Agarwal; Amitabha Chakrabarti; David N Wald
Securinine, a myeloid differentiation agent with therapeutic potential for AML.
PloS one 2011;6(6):e21203.
2011: Susan M Ferguson; Daniel Eskenazi; Masago Ishikawa; Matthew J Wanat; Paul E M Phillips; Yan Dong; Bryan L Roth; John F Neumaier
Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization.
Nature neuroscience 2011;14(1):22-4.
2011: John A Allen; Bryan L Roth
Strategies to discover unexpected targets for drugs active at G protein-coupled receptors.
Annual review of pharmacology and toxicology 2011;51():117-44.
2010: Xi-Ping Huang; Thomas Mangano; Sandy Hufeisen; Vincent Setola; Bryan L Roth
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Assay and drug development technologies 2010;8(6):727-42.
2010: Bradford D Fischer; Stephanie C Licata; Rahul V Edwankar; Zhi-Jian Wang; Shengming Huang; Xiaohui He; Jianming Yu; Hao Zhou; Edward M Johnson; James M Cook; Roman Furtmüller; Joachim Ramerstorfer; Werner Sieghart; Bryan L Roth; Samarpan Majumder; James K Rowlett
Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure.
Neuropharmacology 2010;59(7-8):612-8.
2010: Rima Hajjo; Christopher M Grulke; Alexander Golbraikh; Vincent Setola; Xi-Ping Huang; Bryan L Roth; Alexander Tropsha
Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry 2010;53(21):7573-86.
2010: Wenyuan Yin; Samarpan Majumder; Terry Clayton; Steven Petrou; Michael L VanLinn; Ojas A Namjoshi; C Ma; Brett A Cromer; Bryan L Roth; Donna M Platt; James M Cook
Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.
Bioorganic & medicinal chemistry 2010;18(21):7548-64.
2010: Geneviève Laroche; Patrick M Giguère; Bryan L Roth; JoAnn Trejo; David Siderovski
RNA interference screen for RGS protein specificity at muscarinic and protease-activated receptors reveals bidirectional modulation of signaling.
American journal of physiology. Cell physiology 2010;299(3):C654-64.
2010: Alan P Kozikowski; Sung Jin Cho; Niels H Jensen; John A Allen; Andreas Svennebring; Bryan L Roth
HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.
ChemMedChem 2010;5(8):1221-5.
2010: Shuyun Dong; John A Allen; Martilias Farrell; Bryan L Roth
A chemical-genetic approach for precise spatio-temporal control of cellular signaling.
Molecular bioSystems 2010;6(8):1376-80.
2010: Christina L Nemeth; Tracie Paine; Joseph E Rittiner; Cécile Béguin; F Ivy Carroll; Bryan L Roth; Bruce M Cohen; William A Carlezon
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.
Psychopharmacology 2010;210(2):263-74.
2010: Atheir I Abbas; Daniel J Urban; Niels H Jensen; Martilias S Farrell; Wesley K Kroeze; Piotr Mieczkowski; Zefeng Wang; Bryan L Roth
Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method.
Nucleic acids research 2010;38(10):e118.
2010: Donna L McGovern; Philip D Mosier; Bryan L Roth; Richard B Westkaemper
CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.
Journal of molecular graphics & modelling 2010;28(7):612-25.
2010: Ryan T Strachan; John A Allen; Douglas J Sheffler; Bryan L Roth
p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling.
Biochemistry 2010;49(12):2657-71.
2010: Miroslav M Savić; Samarpan Majumder; Shengming Huang; Rahul V Edwankar; Roman Furtmüller; Srdjan Joksimovic; Terry Clayton; Joachim Ramerstorfer; Marija M Milinković; Bryan L Roth; Werner Sieghart; James M Cook
Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?
Progress in neuro-psychopharmacology & biological psychiatry 2010;34(2):376-86.
2010: Shuyun Dong; Sarah C Rogan; Bryan L Roth
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs.
Nature protocols 2010;5(3):561-73.
2010: Martilias Farrell; Bryan L Roth
Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010;35(4):851-2.
2010: Ryan T Strachan; Noah Sciaky; Mark R Cronan; Wesley K Kroeze; Bryan L Roth
Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity.
Molecular pharmacology 2010;77(3):327-38.
2010: Jitesh R Shah; Philip D Mosier; Srinivas Peddi; Bryan L Roth; Richard B Westkaemper
9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.
Bioorganic & medicinal chemistry letters 2010;20(3):935-8.
2010: Richard A Glennon; Uma Siripurapu; Bryan L Roth; Renata Kolanos; Mikhail L Bondarev; Donald Sikazwe; Mase Lee; Malgorzata Dukat
The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs.
Current topics in medicinal chemistry 2010;10(5):579-95.
2010: Ying Pei; Shuyun Dong; Bryan L Roth
Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution.
Current protocols in neuroscience / editorial board, Jacqueline N. Crawley ... [et al.] 2010;Chapter 4():Unit 4.33.
2009: Kelly A Jones; Deepak P Srivastava; John A Allen; Ryan T Strachan; Bryan L Roth; Peter Penzes
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(46):19575-80.
2009: Michael J Keiser; Vincent Setola; John J Irwin; Christian Laggner; Atheir I Abbas; Sandra J Hufeisen; Niels H Jensen; Michael B Kuijer; Roberto C Matos; Thuy B Tran; Ryan Whaley; Richard A Glennon; Jérôme Hert; Kelan L H Thomas; Douglas D Edwards; Brian Shoichet; Bryan L Roth
Predicting new molecular targets for known drugs.
Nature 2009;462(7270):175-81.
2009: Jean-Marc Guettier; Dinesh Gautam; Marco Scarselli; Inigo Ruiz de Azua; Jian Hua Li; Erica Rosemond; Xiaochao Ma; Frank J Gonzalez; Blaine N Armbruster; Huiyan Lu; Bryan L Roth; Jürgen Wess
A chemical-genetic approach to study G protein regulation of beta cell function in vivo.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(45):19197-202.
2009: John A Allen; jiangzhou yu; Rahul H Dave; Anushree Bhatnagar; Bryan L Roth; Mark M Rasenick
Caveolin-1 and lipid microdomains regulate Gs trafficking and attenuate Gs/adenylyl cyclase signaling.
Molecular pharmacology 2009;76(5):1082-93.
2009: Xi-Ping Huang; Vincent Setola; Prem N Yadav; John A Allen; Sarah C Rogan; Bonnie J Hanson; Chetana Revankar; Matt Robers; Chris Doucette; Bryan L Roth
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.
Molecular pharmacology 2009;76(4):710-22.
2009: Jitesh R Shah; Philip D Mosier; Bryan L Roth; Glen E Kellogg; Richard B Westkaemper
Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.
Bioorganic & medicinal chemistry 2009;17(18):6496-504.
2009: Feng Yan; Ruslan V Bikbulatov; Viorel Mocanu; Nedyalka Dicheva; Carol Parker; William C Wetsel; Philip D Mosier; Richard B Westkaemper; John A Allen; Jordan K Zjawiony; Bryan L Roth
Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.
Biochemistry 2009;48(29):6898-908.
2009: Adam Jordan Kimple; Meera Soundararajan; Stephanie Q Hutsell; Annette K Roos; Daniel J Urban; Vincent Setola; Brenda Temple; Bryan L Roth; Stefan Knapp; Francis S Willard; David Siderovski
Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2).
The Journal of biological chemistry 2009;284(29):19402-11.
2009: Georgia M Alexander; Sarah C Rogan; Atheir I Abbas; Blaine N Armbruster; Ying Pei; John A Allen; Randal J Nonneman; John Hartmann; Sheryl S Moy; Miguel Nicolelis; James O McNamara; Bryan L Roth
Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors.
Neuron 2009;63(1):27-39.
2009: Jong Yeon Hwang; Leggy Arnold; Fangyi Zhu; Aaron Kosinski; Thomas J Mangano; Vincent Setola; Bryan L Roth; R Kiplin Guy
Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.
Journal of medicinal chemistry 2009;52(13):3892-901.
2009: Atheir I Abbas; Peter B Hedlund; Xi-Ping Huang; Thuy B Tran; Herbert Y Meltzer; Bryan L Roth
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.
Psychopharmacology 2009;205(1):119-28.
2009: Atheir I Abbas; Prem N Yadav; Wei-Dong Yao; Margaret I Arbuckle; Seth G N Grant; Marc G Caron; Bryan L Roth
PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2009;29(22):7124-36.
2009: Dorota Zolkowska; Raka Jain; Richard B Rothman; John S Partilla; Bryan L Roth; Vincent Setola; Thomas E Prisinzano; Michael H Baumann
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
The Journal of pharmacology and experimental therapeutics 2009;329(2):738-46.
2009: Sung Jin Cho; Niels H Jensen; Toru Kurome; Sudhakar Kadari; Michael L Manzano; Jessica E Malberg; Barbara Caldarone; Bryan L Roth; Alan P Kozikowski
Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.
Journal of medicinal chemistry 2009;52(7):1885-902.
2009: Felix M Rivas; James P Stables; Lauren Murphree; Rahul V Edwankar; Chitra R Edwankar; Shengming Huang; Hiteshkumar D Jain; Hao Zhou; Samarpan Majumder; Subramanian Sankar; Bryan L Roth; Joachim Ramerstorfer; Roman Furtmüller; Werner Sieghart; James M Cook
Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models.
Journal of medicinal chemistry 2009;52(7):1795-8.
2009: Ryan T Strachan; Douglas J Sheffler; Belinda B Willard; Michael Kinter; Janna G Kiselar; Bryan L Roth
Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signaling.
The Journal of biological chemistry 2009;284(9):5557-73.
2009: Donald M N Sikazwe; Nancy T Nkansah; Ramazan Altundas; Xue Y Zhu; Bryan L Roth; Vincent Setola; Seth Y Ablordeppey
Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups.
Bioorganic & medicinal chemistry 2009;17(4):1716-23.
2009: Hao Tang; Xiang Wang; Xi-Ping Huang; Bryan L Roth; Kyle V Butler; Alan P Kozikowski; Mira Jung; Alexander Tropsha
Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Journal of chemical information and modeling 2009;49(2):461-76.
2009: Charles D Nichols; Bryan L Roth
Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors.
Frontiers in molecular neuroscience 2009;2():16.
2009: Miles Berger; John A Gray; Bryan L Roth
The expanded biology of serotonin.
Annual review of medicine 2009;60():355-66.
2008: Ying Pei; Sarah C Rogan; Feng Yan; Bryan L Roth
Engineered GPCRs as tools to modulate signal transduction.
Physiology (Bethesda, Md.) 2008;23():313-21.
2008: Atheir Abbas; Bryan L Roth
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Expert opinion on pharmacotherapy 2008;9(18):3251-9.
2008: Scott P Runyon; Philip D Mosier; Bryan L Roth; Richard A Glennon; Richard B Westkaemper
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
Journal of medicinal chemistry 2008;51(21):6808-28.
2008: John A Allen; Prem N Yadav; Bryan L Roth
Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases.
Neuropharmacology 2008;55(6):961-8.
2008: Atheir Abbas; Bryan L Roth
Protein engineering: electrifying cell receptors.
Nature nanotechnology 2008;3(10):587-8.
2008: Dongmei Han; F Holger Försterling; Xiaoyan Li; Jeffrey Deschamps; Damon Parrish; Hui Cao; Sundari Rallapalli; Terry Clayton; Yun Teng; Samarpan Majumder; Subramaniam Sankar; Bryan L Roth; Werner Sieghart; Roman Furtmuller; James K Rowlett; Michael Weed; James M Cook
A study of the structure-activity relationship of GABA(A)-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis.
Bioorganic & medicinal chemistry 2008;16(19):8853-62.
2008: Gajanan K Dewkar; Srinivas Peddi; Philip D Mosier; Bryan L Roth; Richard B Westkaemper
Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor.
Bioorganic & medicinal chemistry letters 2008;18(19):5268-71.
2008: Gregory J Basura; Atheir I Abbas; Heather O'Donohue; Jean M Lauder; Bryan L Roth; Paul D Walker; Paul B Manis
Ontogeny of serotonin and serotonin2A receptors in rat auditory cortex.
Hearing research 2008;244(1-2):45-50.
2008: Vindhya Nawaratne; Katie Leach; Nur Suratman; Richard E Loiacono; Christian Felder; Blaine N Armbruster; Bryan L Roth; Patrick M Sexton; Arthur Christopoulos
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).
Molecular pharmacology 2008;74(4):1119-31.
2008: Niels H Jensen; Ramona M Rodriguiz; Marc G Caron; William C Wetsel; Richard B Rothman; Bryan L Roth
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(10):2303-12.
2008: Bruce R Conklin; Edward C Hsiao; Sylvie Claeysen; Aline Dumuis; Supriya Srinivasan; John R Forsayeth; Jean-Marc Guettier; W C Chang; Ying Pei; Kenny Mccarthy; Robert A Nissenson; Jürgen Wess; Joël Bockaert; Bryan L Roth
Engineering GPCR signaling pathways with RASSLs.
Nature methods 2008;5(8):673-8.
2008: Seth Y Ablordeppey; Ramazan Altundas; Barbara Bricker; Xue Y Zhu; Eyunni V K Suresh Kumar; Tanise Jackson; Abdul Khan; Bryan L Roth
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Bioorganic & medicinal chemistry 2008;16(15):7291-301.
2008: P Jeffrey Conn; Bryan L Roth
Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(9):2048-60.
2008: Niels H Jensen; Bryan L Roth
Massively parallel screening of the receptorome.
Combinatorial chemistry & high throughput screening 2008;11(6):420-6.
2008: David N Wald; Hanna M Vermaat; Shaolei Zang; Andrew Lavik; Zizhen Kang; Gil Peleg; Stanton L Gerson; Kevin D Bunting; Munna L Agarwal; Bryan L Roth; William Tse
Identification of 6-benzylthioinosine as a myeloid leukemia differentiation-inducing compound.
Cancer research 2008;68(11):4369-76.
2008: Malgorzata Dukat; Philip D Mosier; Renata Kolanos; Bryan L Roth; Richard A Glennon
Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies.
Journal of medicinal chemistry 2008;51(3):603-11.
2008: Feng Yan; Philip D Mosier; Richard B Westkaemper; Bryan L Roth
Galpha-subunits differentially alter the conformation and agonist affinity of kappa-opioid receptors.
Biochemistry 2008;47(6):1567-78.
2008: Bryan L Roth
High-dose olanzapine for treatment-resistant schizophrenia.
The Journal of clinical psychiatry 2008;69(2):176-7.
2008: Atheir Abbas; Bryan L Roth
Arresting serotonin.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(3):831-2.
2008: Zhong-Ze Ma; Wei Xu; Niels H Jensen; Bryan L Roth; Lee-Yuan Liu-Chen; David Y W Lee
Isoquinoline alkaloids isolated from Corydalis yanhusuo and their binding affinities at the dopamine D1 receptor.
Molecules (Basel, Switzerland) 2008;13(9):2303-12.
2008: Cécile Béguin; David N Potter; Jennifer A DiNieri; Thomas Munro; Michele R Richards; Tracie Paine; Loren Berry; Zhiyang Zhao; Bryan L Roth; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen
N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.
The Journal of pharmacology and experimental therapeutics 2008;324(1):188-95.
2007: Clelia Dallanoce; Marco De Amici; Elisabetta Barocelli; Simona Bertoni; Bryan L Roth; Paul Ernsberger; Carlo De Micheli
Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes.
Bioorganic & medicinal chemistry 2007;15(24):7626-37.
2007: Per Svenningsson; Helen Bateup; Hongshi Qi; Kogo Takamiya; Richard Huganir; Michael Spedding; Bryan L Roth; Bruce S McEwen; Paul Greengard
Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine.
The European journal of neuroscience 2007;26(12):3509-17.
2007: Bryan L Roth
An Interview with Bryan Roth, M.D., Ph.D.
Assay and drug development technologies 2007;5(5):593-8.
2007: J A Gray; Bryan L Roth
The pipeline and future of drug development in schizophrenia.
Molecular psychiatry 2007;12(10):904-22.
2007: John A Gray; Bryan L Roth
Molecular targets for treating cognitive dysfunction in schizophrenia.
Schizophrenia bulletin 2007;33(5):1100-19.
2007: Ruslan V Bikbulatov; Feng Yan; Bryan L Roth; Jordan K Zjawiony
Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B.
Bioorganic & medicinal chemistry letters 2007;17(8):2229-32.
2007: Blaine N Armbruster; Xiang Li; Mark H Pausch; Stefan Herlitze; Bryan L Roth
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(12):5163-8.
2007: Pascal Carato; Amaury Graulich; Niels Jensen; Bryan L Roth; Jean-François Liégeois
Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the position of the amide on the affinity for D2L, D4.2, and 5-HT2A receptors.
Bioorganic & medicinal chemistry letters 2007;17(6):1565-9.
2007: Pascal Carato; Amaury Graulich; Niels Jensen; Bryan L Roth; Jean-François Liégeois
Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D2L, D4.2, and 5-HT2A receptors.
Bioorganic & medicinal chemistry letters 2007;17(6):1570-4.
2007: Abner Nyandege; Renata Kolanos; Bryan L Roth; Richard A Glennon
Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors.
Bioorganic & medicinal chemistry letters 2007;17(6):1691-4.
2007: Timothy A Vortherms; Philip D Mosier; Richard B Westkaemper; Bryan L Roth
Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.
The Journal of biological chemistry 2007;282(5):3146-56.
2007: Michael J Keiser; Bryan L Roth; Blaine N Armbruster; Paul Ernsberger; John J Irwin; Brian Shoichet
Relating protein pharmacology by ligand chemistry.
Nature biotechnology 2007;25(2):197-206.
2007: Bryan L Roth
Drugs and valvular heart disease.
The New England journal of medicine 2007;356(1):6-9.
2007: Jonathan D Urban; William Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; HAREL WEINSTEIN; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Functional selectivity and classical concepts of quantitative pharmacology.
The Journal of pharmacology and experimental therapeutics 2007;320(1):1-13.
2006: Renata Kolanos; Malgorzata Dukat; Bryan L Roth; Richard A Glennon
Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors.
Bioorganic & medicinal chemistry letters 2006;16(22):5832-5.
2006: Sivaraman Dandapani; Ping Lan; Aaron B Beeler; Scott Beischel; Athier Abbas; Bryan L Roth; John A Porco; James S Panek
Convergent synthesis of complex diketopiperazines derived from pipecolic acid scaffolds and parallel screening against GPCR targets.
The Journal of organic chemistry 2006;71(23):8934-45.
2006: Timothy A Vortherms; Bryan L Roth
Salvinorin A: from natural product to human therapeutics.
Molecular interventions 2006;6(5):257-65.
2006: Benjamin R Chemel; Bryan L Roth; Blaine Armbruster; Val Watts; David E Nichols
WAY-100635 is a potent dopamine D4 receptor agonist.
Psychopharmacology 2006;188(2):244-51.
2006: Alan P Kozikowski; Bryan L Roth; Alexander Tropsha
Why academic drug discovery makes sense.
Science (New York, N.Y.) 2006;313(5791):1235-6.
2006: Donald Sikazwe; Mikhail L Bondarev; Malgorzata Dukat; Jagadeesh B Rangisetty; Bryan L Roth; Richard A Glennon
Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors.
Journal of medicinal chemistry 2006;49(17):5217-25.
2006: Ryan T Strachan; Gina Ferrara; Bryan L Roth
Screening the receptorome: an efficient approach for drug discovery and target validation.
Drug discovery today 2006;11(15-16):708-16.
2006: Micheal Ansonoff; Jiwen Zhang; Traci A Czyzyk; Richard B Rothman; Jeremy Stewart; Heng Xu; Jordan Zjwiony; Daniel J Siebert; Feng Yang; Bryan L Roth; John E Pintar
Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(2):641-8.
2006: Uma Siripurapu; Renata Kolanos; Malgorzata Dukat; Bryan L Roth; Richard A Glennon
Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors.
Bioorganic & medicinal chemistry letters 2006;16(14):3793-6.
2006: Wesley K Kroeze; Bryan L Roth
Screening the receptorome.
Journal of psychopharmacology (Oxford, England) 2006;20(4 Suppl):41-6.
2006: Seth Y Ablordeppey; Margaret Lyles-Eggleston; Barbara Bricker; Wang Zhang; Xue Zhu; Carl Goodman; Bryan L Roth
Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.
Bioorganic & medicinal chemistry letters 2006;16(12):3219-23.
2006: Neena Kushwaha; Shannon C Harwood; Ariel M Wilson; Miles Berger; Laurence H Tecott; Bryan L Roth; Paul R Albert
Molecular determinants in the second intracellular loop of the 5-hydroxytryptamine-1A receptor for G-protein coupling.
Molecular pharmacology 2006;69(5):1518-26.
2006: Douglas J Sheffler; Wesley K Kroeze; Bonnie G Garcia; Ariel Deutch; Sandra J Hufeisen; Patrick Leahy; Jens C Brüning; Bryan L Roth
p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4717-22.
2006: Yasuyoshi Iso; Ewa Grajkowska; Jarda T Wroblewski; Jared Davis; Nicholas E Goeders; Kenneth M Johnson; Subramaniam Sanker; Bryan L Roth; Werner Tueckmantel; Alan P Kozikowski
Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications.
Journal of medicinal chemistry 2006;49(3):1080-100.
2006: Elizabeth A Pehek; Christine Nocjar; Bryan L Roth; Tara A Byrd; Omar S Mabrouk
Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(2):265-77.
2006: Bryan L Roth
Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
Dialogues in clinical neuroscience 2006;8(3):303-9.
2006: D Jeremy Stewart; Hesham Fahmy; Bryan L Roth; Feng Yan; Jordan K Zjawiony
Bioisosteric modification of salvinorin A, a potent and selective kappa-opioid receptor agonist.
Arzneimittel-Forschung 2006;56(4):269-75.
2006: Bryan L Roth; Wesley K Kroeze
Screening the receptorome yields validated molecular targets for drug discovery.
Current pharmaceutical design 2006;12(14):1785-95.
2006: Marilyn A Davies; Vincent Setola; R T Strachan; Douglas J Sheffler; E Salay; Sandra J Hufeisen; Bryan L Roth
Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies.
The pharmacogenomics journal 2006;6(1):42-51.
2005: Kerry Ann O'Connor; Bryan L Roth
Screening the receptorome for plant-based psychoactive compounds.
Life sciences 2005;78(5):506-11.
2005: Kerry A O'Connor; Bryan L Roth
Finding new tricks for old drugs: an efficient route for public-sector drug discovery.
Nature reviews. Drug discovery 2005;4(12):1005-14.
2005: Manik R Pullagurla; Uma Siripurapu; Renata Kolanos; Mikhail L Bondarev; Malgorzata Dukat; Vincent Setola; Bryan L Roth; Richard A Glennon
Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors.
Bioorganic & medicinal chemistry letters 2005;15(23):5298-302.
2005: Thomas Munro; Glenn W Goetchius; Bryan L Roth; Timothy A Vortherms; Mark A Rizzacasa
Autoxidation of salvinorin A under basic conditions.
The Journal of organic chemistry 2005;70(24):10057-61.
2005: Kåre Søndergaard; Jesper L Kristensen; Mikael Palner; Nic Gillings; Gitte Moos Knudsen; Bryan L Roth; Mikael Begtrup
Synthesis and binding studies of 2-arylapomorphines.
Organic & biomolecular chemistry 2005;3(22):4077-81.
2005: Yiyun Huang; Sung-A Bae; Bryan L Roth; Marc Laruelle
Synthesis of potent and selective serotonin 5-HT1B receptor ligands.
Bioorganic & medicinal chemistry letters 2005;15(21):4786-9.
2005: Howard Sard; Govindaraj Kumaran; Cynthia Morency; Bryan L Roth; Beth Ann Toth; Ping He; Louis Shuster
SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Bioorganic & medicinal chemistry letters 2005;15(20):4555-9.
2005: Vincent Setola; Bryan L Roth
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
Expert opinion on drug metabolism & toxicology 2005;1(3):377-87.
2005: Bryan L Roth
Receptor systems: will mining the receptorome yield novel targets for pharmacotherapy?
Pharmacology & therapeutics 2005;108(1):59-64.
2005: Aaron B Beeler; Dayle E Acquilano; Qibin Su; Feng Yan; Bryan L Roth; James S Panek; John A Porco
Synthesis of a library of complex macrodiolides employing cyclodimerization of hydroxy esters.
Journal of combinatorial chemistry 2005;7(5):673-81.
2005: Carmen Abate; Renata Kolanos; Malgorzata Dukat; Vincent Setola; Bryan L Roth; Richard A Glennon
Interaction of chiral MS-245 analogs at h5-HT6 receptors.
Bioorganic & medicinal chemistry letters 2005;15(15):3510-3.
2005: Atheir Abbas; Bryan L Roth
Progress towards better understanding and treatment of major psychiatric illnesses.
Drug discovery today 2005;10(14):960-2.
2005: Vincent Setola; Malgorzata Dukat; Richard A Glennon; Bryan L Roth
Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.
Molecular pharmacology 2005;68(1):20-33.
2005: Feng Yan; Philip D Mosier; Richard B Westkaemper; Jeremy Stewart; Jordan K Zjawiony; Timothy A Vortherms; Douglas J Sheffler; Bryan L Roth
Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors.
Biochemistry 2005;44(24):8643-51.
2005: Timothy A Vortherms; Bryan L Roth
Receptorome screening for CNS drug discovery.
IDrugs : the investigational drugs journal 2005;8(6):491-6.
2005: Richard B Rothman; Bruce E Blough; William L Woolverton; Karen G Anderson; S Stevens Negus; Nancy K Mello; Bryan L Roth; Michael H Baumann
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.
The Journal of pharmacology and experimental therapeutics 2005;313(3):1361-9.
2005: Renata Kolanos; Uma Siripurapu; Manik R Pullagurla; Mohamed Riaz; Vincent Setola; Bryan L Roth; Malgorzata Dukat; Richard A Glennon
Binding of isotryptamines and indenes at h5-HT6 serotonin receptors.
Bioorganic & medicinal chemistry letters 2005;15(8):1987-91.
2005: Yiyun Huang; Sung-A Bae; Zhihong Zhu; Ningning Guo; Bryan L Roth; Marc Laruelle
Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.
Journal of medicinal chemistry 2005;48(7):2559-70.
2005: Marilyn A Davies; Beth A Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?
Psychopharmacology 2005;178(4):451-60.
2005: Mase Lee; Jagadeesh B Rangisetty; Manik R Pullagurla; Malgorzata Dukat; Vincent Setola; Bryan L Roth; Richard A Glennon
1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands.
Bioorganic & medicinal chemistry letters 2005;15(6):1707-11.
2005: Blaine N Armbruster; Bryan L Roth
Mining the receptorome.
The Journal of biological chemistry 2005;280(7):5129-32.
2005: Matthew S Goldberg; Antonio Pisani; Marian Haburcak; Timothy A Vortherms; Tohru Kitada; Cinzia Costa; Youren Tong; giuseppina martella; Anne Tscherter; Andrea Martins; Giorgio Bernardi; Bryan L Roth; Emmanuel N Pothos; Paolo Calabresi; Jie Shen
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.
Neuron 2005;45(4):489-96.
2005: David Alagille; Ronald M Baldwin; Bryan L Roth; Jarda T Wroblewski; Ewa Grajkowska; Gilles Tamagnan
Functionalization at position 3 of the phenyl ring of the potent mGluR5 noncompetitive antagonists MPEP.
Bioorganic & medicinal chemistry letters 2005;15(4):945-9.
2005: Thomas Munro; Mark A Rizzacasa; Bryan L Roth; Beth A Toth; Feng Yan
Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.
Journal of medicinal chemistry 2005;48(2):345-8.
2005: David Alagille; Ronald M Baldwin; Bryan L Roth; Jarda T Wroblewski; Ewa Grajkowska; Gilles Tamagnan
Synthesis and receptor assay of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity.
Bioorganic & medicinal chemistry 2005;13(1):197-209.
2004: Beata Karolewicz; Katalin Szebeni; Craig A Stockmeier; Lisa C Konick; James C Overholser; George J Jurjus; Bryan L Roth; Gregory A Ordway
Low nNOS protein in the locus coeruleus in major depression.
Journal of neurochemistry 2004;91(5):1057-66.
2004: Gwendolyn F Elphick; William Querbes; Joslynn A Jordan; Gretchen V Gee; Sylvia Eash; Kate Manley; Aisling S Dugan; Megan Stanifer; Anushree Bhatnagar; Wesley K Kroeze; Bryan L Roth; Walter J Atwood
The human polyomavirus, JCV, uses serotonin receptors to infect cells.
Science (New York, N.Y.) 2004;306(5700):1380-3.
2004: Feng Yan; Bryan L Roth
Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.
Life sciences 2004;75(22):2615-9.
2004: Kimberly A Petrie; Michael Bubser; Cheryl D Casey; Michael Davis; Bryan L Roth; Ariel Deutch
The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(10):1878-88.
2004: Phillip L Quirk; Suma Rao; Bryan L Roth; Ruth E Siegel
Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells.
Journal of neuroscience research 2004;77(4):498-506.
2004: Anushree Bhatnagar; Douglas J Sheffler; Wesley K Kroeze; Beth A Compton-Toth; Bryan L Roth
Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors.
The Journal of biological chemistry 2004;279(33):34614-23.
2004: Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.
Psychopharmacology 2004;174(1):17-24.
2004: Srinivas Peddi; Bryan L Roth; Richard A Glennon; Richard B Westkaemper
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
Bioorganic & medicinal chemistry letters 2004;14(9):2279-83.
2004: Bryan L Roth; Estela Lopez; Scott Beischel; Richard B Westkaemper; Jon M Evans
Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery.
Pharmacology & therapeutics 2004;102(2):99-110.
2004: Jean Chang-Fong; Jagadeesh B Rangisetty; Malgorzata Dukat; Vincent Setola; Thomas Raffay; Bryan L Roth; Richard A Glennon
1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands.
Bioorganic & medicinal chemistry letters 2004;14(8):1961-4.
2004: Bryan L Roth; Douglas J Sheffler; Wesley K Kroeze
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.
Nature reviews. Drug discovery 2004;3(4):353-9.
2004: Charles Chavkin; Sumit Sud; Wenzhen Jin; Jeremy Stewart; Jordan K Zjawiony; Daniel J Siebert; Beth Ann Toth; Sandra J Hufeisen; Bryan L Roth
Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
The Journal of pharmacology and experimental therapeutics 2004;308(3):1197-203.
2004: Gerard J O'Sullivan; Bryan L Roth; Anthony Kinsella; John L Waddington
SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
European journal of pharmacology 2004;486(3):273-80.
2004: Bryan L Roth; Zongqi Xia
Molecular and cellular mechanisms for the polarized sorting of serotonin receptors: relevance for genesis and treatment of psychosis.
Critical reviews in neurobiology 2004;16(4):229-36.
2004: Marilyn A Davies; Douglas J Sheffler; Bryan L Roth
Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
CNS drug reviews 2004;10(4):317-36.
2003: Srinivas Peddi; Bryan L Roth; Richard A Glennon; Richard B Westkaemper
Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist.
European journal of pharmacology 2003;482(1-3):335-7.
2003: Wesley K Kroeze; Douglas J Sheffler; Bryan L Roth
G-protein-coupled receptors at a glance.
Journal of cell science 2003;116(Pt 24):4867-9.
2003: John E Piletz; W Deleersnijder; Bryan L Roth; Paul Ernsberger; Hong Zhu; D Ziegler
IRAS splice variants.
Annals of the New York Academy of Sciences 2003;1009():419-26.
2003: Vincent Setola; Bryan L Roth
Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants.
Molecular pharmacology 2003;64(6):1277-8.
2003: Qi Shi; Sandra J Hufeisen; Jarda T Wroblewski; Joseph H Nadeau; Bryan L Roth
L-homocysteine sulfinic acid and L-homocysteic acid stimulate phosphoinositide hydrolysis in rat cortical neurons.
Annals of the New York Academy of Sciences 2003;1003():461-3.
2003: Matthew S Goldberg; Sheila M Fleming; James J Palacino; Carlos Cepeda; Hoa A Lam; Anushree Bhatnagar; Edward G Meloni; Nanping Wu; Larry C Ackerson; Gloria J Klapstein; Mahadevan Gajendiran; Bryan L Roth; Marie-Francoise Chesselet; Nigel T Maidment; Michael S Levine; Jie Shen
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.
The Journal of biological chemistry 2003;278(44):43628-35.
2003: Manik R Pullagurla; Malgorzata Dukat; Vincent Setola; Bryan L Roth; Richard A Glennon
N1-benzenesulfonylgramine and N1-benzenesulfonylskatole: novel 5-HT6 receptor ligand templates.
Bioorganic & medicinal chemistry letters 2003;13(19):3355-9.
2003: Richard B Rothman; Nga Vu; John S Partilla; Bryan L Roth; Sandra J Hufeisen; Beth A Compton-Toth; Jon Birkes; Richard Young; Richard A Glennon
In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates.
The Journal of pharmacology and experimental therapeutics 2003;307(1):138-45.
2003: John A Gray; Beth A Compton-Toth; Bryan L Roth
Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization.
Biochemistry 2003;42(36):10853-62.
2003: Marco De Amici; Paola Conti; Ezio Fasoli; Elisabetta Barocelli; Vigilio Ballabeni; Simona Bertoni; Mariannina Impicciatore; Bryan L Roth; Paul Ernsberger; Carlo De Micheli
Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands.
Farmaco (Società chimica italiana : 1989) 2003;58(9):739-48.
2003: Srinivas Peddi; Bryan L Roth; Richard A Glennon; Richard B Westkaemper
Ring substituted analogues of 5-aminomethyl-10,11-dihydro-dibenzo[a,d]cycloheptene (AMDH): potential modes of binding to the 5-HT(2A) receptor.
Bioorganic & medicinal chemistry letters 2003;13(15):2565-8.
2003: David A Shapiro; Sean Renock; Elaine Arrington; Louis A Chiodo; Li-Xin Liu; David R Sibley; Bryan L Roth; Richard B Mailman
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(8):1400-11.
2003: Zongqi Xia; John A Gray; Beth A Compton-Toth; Bryan L Roth
A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction.
The Journal of biological chemistry 2003;278(24):21901-8.
2003: Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
Molecular pharmacology 2003;63(6):1223-9.
2003: John A Gray; Anushree Bhatnagar; Vsevolod V Gurevich; Bryan L Roth
The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT(2A) receptor induces agonist-independent internalization.
Molecular pharmacology 2003;63(5):961-72.
2003: Qi Shi; Jason E Savage; Sandra J Hufeisen; Laura Rauser; Ewa Grajkowska; Paul Ernsberger; Jarda T Wroblewski; Joseph H Nadeau; Bryan L Roth
L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.
The Journal of pharmacology and experimental therapeutics 2003;305(1):131-42.
2003: Wesley K Kroeze; Sandra J Hufeisen; Beth A Popadak; Sean Renock; SeAnna Steinberg; Paul Ernsberger; Karu Jayathilake; Herbert Y Meltzer; Bryan L Roth
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(3):519-26.
2003: Douglas J Sheffler; Bryan L Roth
Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
Trends in pharmacological sciences 2003;24(3):107-9.
2003: Alan Faden; Susan M Knoblach; Ibolja Cernak; Lei Fan; Robert Vink; Gian Luca Araldi; Stanley T Fricke; Bryan L Roth; Alan P Kozikowski
Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2003;23(3):342-54.
2003: Zongqi Xia; Sandra J Hufeisen; John A Gray; Bryan L Roth
The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro.
Neuroscience 2003;122(4):907-20.
2002: Bryan L Roth; Karen Baner; Richard B Westkaemper; Daniel Siebert; Kenner C Rice; SeAnna Steinberg; Paul Ernsberger; Richard B Rothman
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11934-9.
2002: John A Gray; Bryan L Roth
Cell biology. A last GASP for GPCRs?
Science (New York, N.Y.) 2002;297(5581):529-31.
2002: Veronika Butterweck; Adolf Nahrstedt; Jon Evans; Sandra J Hufeisen; Laura Rauser; Jason Savage; Beth Popadak; Paul Ernsberger; Bryan L Roth
In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.
Psychopharmacology 2002;162(2):193-202.
2002: Wesley K Kroeze; Kurt Kristiansen; Bryan L Roth
Molecular biology of serotonin receptors structure and function at the molecular level.
Current topics in medicinal chemistry 2002;2(6):507-28.
2002: Scott P Runyon; Srinivas Peddi; Jason E Savage; Bryan L Roth; Richard A Glennon; Richard B Westkaemper
Geometry-affinity relationships of the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
Journal of medicinal chemistry 2002;45(8):1656-64.
2002: David A Shapiro; Kurt Kristiansen; David M Weiner; Wesley K Kroeze; Bryan L Roth
Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.
The Journal of biological chemistry 2002;277(13):11441-9.
2002: V Cornea-Hébert; Kenneth C Watkins; Bryan L Roth; W K Kroeze; P Gaudreau; N Leclerc; Laurent Descarries
Similar ultrastructural distribution of the 5-HT(2A) serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat.
Neuroscience 2002;113(1):23-35.
2002: Christine Nocjar; Bryan L Roth; Elizabeth A Pehek
Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group.
Neuroscience 2002;111(1):163-76.
2001: Raúl Martín-Ruiz; M Victoria Puig; Pau Celada; D A Shapiro; Bryan L Roth; Guadalupe Mengod; Francesc Artigas
Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(24):9856-66.
2001: John A Gray; Bryan L Roth
Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists.
Brain research bulletin 2001;56(5):441-51.
2001: John A Gray; Douglas J Sheffler; Anushree Bhatnagar; J A Woods; Sandra J Hufeisen; JL Benovic; Bryan L Roth
Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells.
Molecular pharmacology 2001;60(5):1020-30.
2001: Laura Rauser; Jason E Savage; Herbert Y Meltzer; Bryan L Roth
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
The Journal of pharmacology and experimental therapeutics 2001;299(1):83-9.
2001: Bryan L Roth; Paul Ernsberger; S A Steinberg; S Rao; Laura Rauser; Jason Savage; Sandra J Hufeisen; Marc S Berridge; Raymond F Muzic
The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.
Psychopharmacology 2001;157(1):111-4.
2001: Yiyun Huang; Lawrence S Kegeles; S Bae; D Hwang; Bryan L Roth; J E Savage; Marc Laruelle
Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.
Bioorganic & medicinal chemistry letters 2001;11(11):1375-7.
2001: L Qiao; L Y Zhao; S B Rong; X W Wu; Shaomeng Wang; T Fujii; Marcelo G Kazanietz; Laura Rauser; Jason Savage; Bryan L Roth; J Flippen-Anderson; Alan P Kozikowski
Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth.
Bioorganic & medicinal chemistry letters 2001;11(8):955-9.
2001: Anushree Bhatnagar; DL Willins; John A Gray; J Woods; JL Benovic; Bryan L Roth
The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis.
The Journal of biological chemistry 2001;276(11):8269-77.
2001: Michael Bubser; Jon R Backstrom; Elaine Sanders-Bush; Bryan L Roth; Ariel Deutch
Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum.
Synapse (New York, N.Y.) 2001;39(4):297-304.
2001: Scott P Runyon; Jason E Savage; M Taroua; Bryan L Roth; Richard A Glennon; Richard B Westkaemper
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
Bioorganic & medicinal chemistry letters 2001;11(5):655-8.
2001: Tuan V Nguyen; D A Shapiro; Susan R George; Vincent Setola; D K Lee; R Cheng; L Rauser; S P Lee; K R Lynch; Bryan L Roth; Brian F O'Dowd
Discovery of a novel member of the histamine receptor family.
Molecular pharmacology 2001;59(3):427-33.
2001: Richard B Westkaemper; Scott P Runyon; Jason E Savage; Bryan L Roth; Richard A Glennon
Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor.
Bioorganic & medicinal chemistry letters 2001;11(4):563-6.
2000: Richard B Rothman; Michael H Baumann; Jason E Savage; Laura Rauser; A McBride; Sandra J Hufeisen; Bryan L Roth
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Circulation 2000;102(23):2836-41.
2000: David A Shapiro; Kurt Kristiansen; Wesley K Kroeze; Bryan L Roth
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
Molecular pharmacology 2000;58(5):877-86.
2000: Y Tsai; Malgorzata Dukat; Abdelmalik Slassi; Neil MacLean; Lidia Demchyshyn; Jason E Savage; Bryan L Roth; S Hufesein; Mase Lee; Richard A Glennon
N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists.
Bioorganic & medicinal chemistry letters 2000;10(20):2295-9.
2000: Bryan L Roth
Neuronal signal transduction pathways: wasteland or the promised land?
Science's STKE : signal transduction knowledge environment 2000;2000(45):pe1.
2000: John E Piletz; TR Ivanov; JD Sharp; Paul Ernsberger; C H Chang; R T Pickard; G Gold; Bryan L Roth; Hong Zhu; JC Jones; James Baldwin; DJ Reis
Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization.
DNA and cell biology 2000;19(6):319-29.
2000: Kurt Kristiansen; Wesley K Kroeze; DL Willins; E I Gelber; Jason E Savage; Richard A Glennon; Bryan L Roth
A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.
The Journal of pharmacology and experimental therapeutics 2000;293(3):735-46.
2000: Richard A Glennon; Mase Lee; Jagadeesh B Rangisetty; Malgorzata Dukat; Bryan L Roth; Jason E Savage; A McBride; Laura Rauser; Sandra J Hufeisen; DK Lee
2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
Journal of medicinal chemistry 2000;43(5):1011-8.
2000: C Egan; Ellinor Grinde; A DuPre; Bryan L Roth; M Hake; Milt Teitler; Katharine Herrick-Davis
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Synapse (New York, N.Y.) 2000;35(2):144-50.
1999: Richard B Westkaemper; Scott P Runyon; Mikhail L Bondarev; Jason E Savage; Bryan L Roth; Richard A Glennon
9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist.
European journal of pharmacology 1999;380(1):R5-7.
1999: Ping-Zhong Tan; Ronald M Baldwin; Christopher H van Dyck; Mohammed S Al-Tikriti; Bryan L Roth; N Khan; Dennis S Charney; Robert B Innis
Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.
Nuclear medicine and biology 1999;26(6):601-8.
1999: Bryan L Roth; DL Willins
What's all the RAVE about receptor internalization?
Neuron 1999;23(4):629-31.
1999: Grazyna Rajkowska; Jose Javier Miguel-Hidalgo; J Wei; GE Dilley; S D Pittman; Herbert Y Meltzer; James C Overholser; Bryan L Roth; Craig A Stockmeier
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression.
Biological psychiatry 1999;45(9):1085-98.
1999: E I Gelber; Wesley K Kroeze; DL Willins; John A Gray; C A Sinar; E G Hyde; Vsevolod V Gurevich; JL Benovic; Bryan L Roth
Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purified arrestins.
Journal of neurochemistry 1999;72(5):2206-14.
1999: DL Willins; SA Berry; L Alsayegh; Jon R Backstrom; Elaine Sanders-Bush; L Friedman; Bryan L Roth
Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo.
Neuroscience 1999;91(2):599-606.
1998: DL Willins; L Alsayegh; SA Berry; Jon R Backstrom; Elaine Sanders-Bush; L Friedman; N Khan; Bryan L Roth
Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo.
Annals of the New York Academy of Sciences 1998;861():121-7.
1998: Wesley K Kroeze; Bryan L Roth
The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis.
Biological psychiatry 1998;44(11):1128-42.
1998: Bryan L Roth; DL Willins; Kurt Kristiansen; Wesley K Kroeze
5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function.
Pharmacology & therapeutics 1998;79(3):231-57.
1998: Bryan L Roth; DL Willins; Wesley K Kroeze
G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse.
Drug and alcohol dependence 1998;51(1-2):73-85.
1998: Bryan L Roth; SA Berry; Wesley K Kroeze; DL Willins; Kurt Kristiansen
Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation.
Critical reviews in neurobiology 1998;12(4):319-38.
1998: Bryan L Roth; Herbert Y Meltzer; N Khan
Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors.
Advances in pharmacology (San Diego, Calif.) 1998;42():482-5.
1997: DL Willins; Ariel Deutch; Bryan L Roth
Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex.
Synapse (New York, N.Y.) 1997;27(1):79-82.
1997: Bryan L Roth; Menachem Shoham; M S Choudhary; N Khan
Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors.
Molecular pharmacology 1997;52(2):259-66.
1997: Bryan L Roth; M S Choudhary; N Khan; A Z Uluer
High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.
The Journal of pharmacology and experimental therapeutics 1997;280(2):576-83.
1996: E P Pälvimäki; Bryan L Roth; H Majasuo; Aki Laakso; M Kuoppamäki; Erkka Syvälahti; Jarmo Hietala
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.
Psychopharmacology 1996;126(3):234-40.
1996: S A Berry; M C Shah; N Khan; Bryan L Roth
Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
Molecular pharmacology 1996;50(2):306-13.
1996: Ruth Kohen; M A Metcalf; N Khan; T Druck; K Huebner; J E Lachowicz; Herbert Y Meltzer; David R Sibley; Bryan L Roth; Mark W Hamblin
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
Journal of neurochemistry 1996;66(1):47-56.
1995: Bryan L Roth; E P Palvimaki; S Berry; N Khan; N Sachs; A Uluer; M S Choudhary
5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation.
The Journal of pharmacology and experimental therapeutics 1995;275(3):1638-46.
1995: Bryan L Roth; S Tandra; L H Burgess; David R Sibley; Herbert Y Meltzer
D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.
Psychopharmacology 1995;120(3):365-8.
1995: M S Choudhary; N Sachs; A Uluer; Richard A Glennon; R B Westkaemper; Bryan L Roth
Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding.
Molecular pharmacology 1995;47(3):450-7.
1994: David E Nichols; S Frescas; Danuta Marona-Lewicka; X Huang; Bryan L Roth; Gary A Gudelsky; J F Nash
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
Journal of medicinal chemistry 1994;37(25):4346-51.
1994: J F Nash; Bryan L Roth; J D Brodkin; D E Nichols; Gary A Gudelsky
Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors.
Neuroscience letters 1994;177(1-2):111-5.
1994: Bryan L Roth
Multiple serotonin receptors: clinical and experimental aspects.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1994;6(2):67-78.
1994: Bryan L Roth; S C Craigo; M S Choudhary; A Uluer; F J Monsma; Y Shen; Herbert Y Meltzer; David R Sibley
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
The Journal of pharmacology and experimental therapeutics 1994;268(3):1403-10.
1993: S J Garlow; David Morilak; R R Dean; Bryan L Roth; R D Ciaranello
Production and characterization of a specific 5-HT2 receptor antibody.
Brain research 1993;615(1):113-20.
1993: M S Choudhary; S Craigo; Bryan L Roth
A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.
Molecular pharmacology 1993;43(5):755-61.
1993: R D Ciaranello; J Aimi; R Dean; R Desai; S Garlow; M R Heller; David Morilak; Bryan L Roth
Developmental regulation of 5-HT2 and 5-HT1c receptor gene expression in rat brain.
Psychopharmacology series 1993;10():26-37.
1992: M S Choudhary; S Craigo; Bryan L Roth
Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors.
Molecular pharmacology 1992;42(4):627-33.
1992: Bryan L Roth; R D Ciaranello; Herbert Y Meltzer
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.
The Journal of pharmacology and experimental therapeutics 1992;260(3):1361-5.
1991: Bryan L Roth; R D Ciaranello
Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels.
European journal of pharmacology 1991;207(2):169-72.
1991: Bryan L Roth; M W Hamblin; R D Ciaranello
Developmental regulation of 5-HT2 and 5-HT1c mRNA and receptor levels.
Brain research. Developmental brain research 1991;58(1):51-8.
1990: Bryan L Roth; Mark W Hamblin; R D Ciaranello
Regulation of 5-HT2 and 5-HT1C serotonin receptor levels. Methodology and mechanisms.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1990;3(5-6):427-33.
1990: M R Seggel; M Y Yousif; R A Lyon; M Titeler; Bryan L Roth; E A Suba; Richard A Glennon
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors.
Journal of medicinal chemistry 1990;33(3):1032-6.
1989: J A Carcillo; R Z Litten; Bryan L Roth
Norepinephrine-induced phosphorylation of a 25 kd phosphoprotein in rat aorta is altered in intraperitoneal sepsis.
Circulatory shock 1989;28(3):257-65.
1989: Bryan L Roth; Michael Iadarola; J P Mehegan; D M Jacobowitz
Immunohistochemical distribution of beta-protein kinase C in rat hippocampus determined with an antibody against a synthetic peptide sequence.
Brain research bulletin 1989;22(5):893-7.
1989: S McLean; R B Rothman; D M Chuang; K C Rice; J W Spain; Carmine J Coscia; Bryan L Roth
Cross-linking of [125I]beta-endorphin to mu-opioid receptors during development.
Brain research. Developmental brain research 1989;45(2):283-9.
1989: J B Hermiller; I Deuciuc; J P Mehegan; J A Spitzer; Bryan L Roth
Alterations in splenic and hepatic protein kinase C in sepsis and chronic endotoxemia.
Progress in clinical and biological research 1989;286():61-70.
1989: Bryan L Roth; J P Mehegan; D M Jacobowitz; F Robey; Michael Iadarola
Rat brain protein kinase C: purification, antibody production, and quantification in discrete regions of hippocampus.
Journal of neurochemistry 1989;52(1):215-21.
1989: J A Spitzer; Ion V Deaciuc; E B Rodriguez de Turco; Bryan L Roth; J B Hermiller; J P Mehegan
Modification of protein kinase C (PKC) activity and diacylglycerol (DAG) accumulation in hepatocytes in continuous endotoxemia.
Progress in clinical and biological research 1989;308():575-88.
1989: J A Spitzer; E B Rodriguez de Turco; Ion V Deaciuc; Bryan L Roth; J B Hermiller; J P Mehegan
Receptor changes in endotoxemia.
Progress in clinical and biological research 1989;299():95-106.
1989: Bryan L Roth; E A Suba; J A Carcillo; R Z Litten
Alterations in hepatic and aortic phospholipase-C coupled receptors and signal transduction in rat intraperitoneal sepsis.
Progress in clinical and biological research 1989;286():41-59.
1988: J A Carcillo; R Z Litten; E A Suba; Bryan L Roth
Alterations in rat aortic alpha 1-adrenoceptors and alpha 1-adrenergic stimulated phosphoinositide hydrolysis in intraperitoneal sepsis.
Circulatory shock 1988;26(3):331-9.
1988: R Z Litten; J A Carcillo; Bryan L Roth
Alterations in bidirectional transmembrane calcium flux occur without changes in protein kinase C levels in rat aorta during sepsis.
Circulatory shock 1988;25(2):123-30.
1987: Bryan L Roth; S McLean; X Z Zhu; D M Chuang
Characterization of two [3H]ketanserin recognition sites in rat striatum.
Journal of neurochemistry 1987;49(6):1833-8.
1987: R Z Litten; E A Suba; Bryan L Roth
Effects of a phorbol ester on rat aortic contraction and calcium influx in the presence and absence of BAY k 8644.
European journal of pharmacology 1987;144(2):185-91.
1987: Bryan L Roth; D M Chuang
Multiple mechanisms of serotonergic signal transduction.
Life sciences 1987;41(9):1051-64.
1987: Bryan L Roth
Modulation of phosphatidylinositol-4,5-bisphosphate hydrolysis in rat aorta by guanine nucleotides, calcium and magnesium.
Life sciences 1987;41(5):629-34.
1987: Bryan L Roth; J Disimone; E A Majane; H Y Yang
Elevation of arterial pressure in rats by two new vertebrate peptides FLFQPQRF-NH2 and AGEGLSSPFWSLAAPQRF-NH2 which are immunoreactive to FMRF-NH2 antiserum.
Neuropeptides 1987;10(1):37-42.
1987: Bryan L Roth; J A Spitzer
Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion.
The American journal of physiology 1987;252(5 Pt 1):E699-702.
1987: E A Suba; Bryan L Roth
Prostaglandins activate phosphoinositide metabolism in rat aorta.
European journal of pharmacology 1987;136(3):325-32.
1987: J A Spitzer; E R Turco; I V Deaciuc; Bryan L Roth
Perturbation of transmembrane signaling mechanisms in acute and chronic endotoxemia.
Progress in clinical and biological research 1987;236A():401-18.
1986: N Ives; J W King; Bart Chernow; Bryan L Roth
BAY k 8644, a calcium channel agonist, reverses hypotension in endotoxin-shocked rats.
European journal of pharmacology 1986;130(3):169-75.
1986: D M Chuang; O Dillon-Carter; J W Spain; M B Laskowski; Bryan L Roth; Carmine J Coscia
Detection and characterization of beta-adrenergic receptors and adenylate cyclase in coated vesicles isolated from bovine brain.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1986;6(9):2578-84.
1986: Bryan L Roth; T Nakaki; D M Chuang; E Costa
5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester.
The Journal of pharmacology and experimental therapeutics 1986;238(2):480-5.
1986: M McMillan; Bart Chernow; Bryan L Roth
Phorbol esters inhibit alpha 1-adrenergic receptor-stimulated phosphoinositide hydrolysis and contraction in rat aorta: evidence for a link between vascular contraction and phosphoinositide turnover.
Biochemical and biophysical research communications 1986;134(2):970-4.
1986: M McMillan; Bart Chernow; Bryan L Roth
Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsis.
Circulatory shock 1986;19(2):185-93.
1986: Bart Chernow; Bryan L Roth
Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches.
Circulatory shock 1986;18(2):141-55.
1986: F Nicoletti; J L Meek; Michael Iadarola; D M Chuang; Bryan L Roth; E Costa
Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus.
Journal of neurochemistry 1986;46(1):40-6.
1985: D B Bennett; J W Spain; M B Laskowski; Bryan L Roth; Carmine J Coscia
Stereospecific opiate-binding sites occur in coated vesicles.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1985;5(11):3010-5.
1985: T Nakaki; Bryan L Roth; D M Chuang; E Costa
5-Hydroxytryptamine uptake and imipramine binding sites in neurotumor NCB-20 cells.
Journal of neurochemistry 1985;45(3):920-5.
1985: T Nakaki; Bryan L Roth; D M Chuang; E Costa
Phasic and tonic components in 5-HT2 receptor-mediated rat aorta contraction: participation of Ca++ channels and phospholipase C.
The Journal of pharmacology and experimental therapeutics 1985;234(2):442-6.
1985: E Legan; Bart Chernow; J Parrillo; Bryan L Roth
Activation of phosphatidylinositol turnover in rat aorta by alpha 1-adrenergic receptor stimulation.
European journal of pharmacology 1985;110(3):389-90.
1985: J W Spain; Bryan L Roth; Carmine J Coscia
Differential ontogeny of multiple opioid receptors (mu, delta, and kappa).
The Journal of neuroscience : the official journal of the Society for Neuroscience 1985;5(3):584-8.
1985: Bryan L Roth; T Nakaki; D M Chuang; E Costa
Evidence for an endacoid for the 5HT2 recognition site.
Progress in clinical and biological research 1985;192():473-6.
1985: Bryan L Roth; M C Beinfeld
The postnatal development of VIP binding sites in rat forebrain and hindbrain.
Peptides 1985;6(1):27-30.
1984: S D Scheibe; D B Bennett; J W Spain; Bryan L Roth; Carmine J Coscia
Kinetic evidence for differential agonist and antagonist binding to bovine hippocampal synaptic membrane opioid receptors.
The Journal of biological chemistry 1984;259(21):13298-303.
1984: M C Beinfeld; D M Korchak; Bryan L Roth; T L O'Donohue
The distribution and chromatographic characterization of PHI (peptide histidine isoleucine amide)-27-like peptides in rat and porcine brain.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1984;4(11):2681-8.
1984: Bryan L Roth; T Nakaki; D M Chuang; E Costa
Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover.
Neuropharmacology 1984;23(10):1223-5.
1984: Bryan L Roth; C J Coscia
Microsomal opiate receptors: characterization of smooth microsomal and synaptic membrane opiate receptors.
Journal of neurochemistry 1984;42(6):1677-84.
1984: Bryan L Roth; M C Beinfeld; A C Howlett
Secretin receptors on neuroblastoma cell membranes: characterization of 125I-labeled secretin binding and association with adenylate cyclase.
Journal of neurochemistry 1984;42(4):1145-52.
1983: J W Spain; D B Bennett; Bryan L Roth; Carmine J Coscia
Ontogeny of benzomorphan-selective (kappa) sites: a computerized analysis.
Life sciences 1983;33 Suppl 1():235-8.
1982: Bryan L Roth; M B Laskowski; Carmine J Coscia
Microsomal opiate receptors differ from synaptic membrane receptors in proteolytic sensitivity.
Brain research 1982;250(1):101-9.
1982: K G Pryhuber; Bryan L Roth; C J Coscia
Demonstration of a slowly dissociating form of bovine hippocampal synaptic membrane opiate receptors.
European journal of pharmacology 1982;83(1-2):47-53.
1982: M Wohltmann; Bryan L Roth; C J Coscia
Differential postnatal development of mu and delta opiate receptors.
Brain research 1982;255(4):679-84.
1981: Bryan L Roth; M B Laskowski; Carmine J Coscia
Evidence for distinct subcellular sites of opiate receptors. Demonstration of opiate receptors in smooth microsomal fractions isolated from rat brain.
The Journal of biological chemistry 1981;256(19):10017-23.
1981: matthew galloway; Bryan L Roth; C J Coscia
The effects of tetrahydroisoquinolinecarboxylic acids in tyrosine 3-monooxygenase.
Archives of biochemistry and biophysics 1981;209(2):620-7.
1980: Bryan L Roth; matthew galloway; C J Coscia
The effects of morphine on catecholamine metabolism during postnatal development.
Brain research 1980;197(2):561-4.
1980: C J Coscia; W J Burke; matthew galloway; A H Kosloff; J M Lasala; J McFarlane; J S Mitchell; M M O'Toole; Bryan L Roth
Effects of norlaudanosolinecarboxylic acids on enzymes of catecholamine metabolism.
The Journal of pharmacology and experimental therapeutics 1980;212(1):91-6.